Recombinant genetic engineering bacteria for preparing nelarabine and its application
Through the biological enzyme catalyst of the recombinant genetically engineered bacteria Escherichia coli 7N04, the problems of complex process and low yield in nairabine synthesis are solved, and efficient and economical nairabine preparation is achieved, which is suitable for industrial production.
Patent Information
- Application Number
- CN202280002989.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-09
- Filing Date
- 2022-06-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-06-09
AI Technical Summary
Among the existing synthesis methods of nairabine, the chemical process is complex and polluted the environment, while the bioconversion method has low yield, difficult to produce converting enzymes, and expensive, and lacks simple, economical and suitable for industrial production.
Using the recombinant genetically engineered bacteria Escherichia coli 7N04, the gene expression of uracil nucleoside phosphorylase and purine nucleoside phosphorylase gene were integrated and co-expressed. The biological enzyme catalyst was obtained through fermentation and culture, which was used to catalyze 2-amino-6-methoxypurine and Bioconversion reaction of aradialyl, preparation of nairabine.
It achieves a high conversion rate of nairabine (≥95%), shortens the enzyme liquid demand and reaction time, reduces production costs, is suitable for industrial production, and has a gentle and environmentally friendly process.
Smart Images

Figure BDA0003826878960000012 
Figure BDA0003826878960000081 
Figure BDA0003826878960000091
Abstract
Description
[0001] Citation of Related Applications
[0002] This application claims priority and benefits of Chinese Patent Application No. 202110641036.8 filed with the State Intellectual Property Office of the People's Republic of China on June 9, 2021, the entire contents of which are hereby incorporated by reference into this document in their entirety. Technical Field
[0003] The present application belongs to the field of biochemical engineering, and specifically relates to a recombinant genetically engineered bacterium for preparing nelarabine and its application. Background Art
[0004] Nelarabine is a cytotoxic drug with the chemical name 9-β-D-arabinofuranosyl-6-methoxy-9H-purine-2-amine. It was approved for marketing by the U.S. Food and Drug Administration (FDA) in October 2005 and its trade name is It is a new drug developed by GlaxoSmithKline for the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that have not responded to more than two chemotherapy treatments or have relapsed. Its structural formula I is shown below:
[0005]
[0006] So far, the synthesis methods of nelarabine disclosed in existing literature and materials mainly include chemical synthesis and biotransformation synthesis. J. Heterocyclic Chem., 1988, 25, 1899-1903 reported a chemical coupling synthesis method using D-arabinose as a raw material, and preparing a compound through multiple steps of protective group reactions to establish a glycosidic bond to obtain nelarabine. Chinese patent CN101092441A discloses that 6-chloroguanosine is used as a raw material, and furanose is converted into arabinose through a six-step chemical synthesis to obtain nelarabine.
[0007] Chinese patent CN1020107C discloses that 2-amino-6-methoxypurine and uracil arabinoside are used as raw materials, incubated at 37°C in pure purine nucleoside phosphorylase and uridine phosphorylase solutions, reacted for 26 days, filtered the reactants, and separated and purified to obtain 2-amino-6-methoxypurine-9-β-D-arabinofuranoside crystals.
[0008] The chemical method has complex processes, harsh reaction conditions, the use of heavy metal reagents, and environmental pollution. In contrast, the biological transformation method has mild reaction conditions, simple steps, and is green and environmentally friendly, but it also has problems such as strict process requirements, low yield, difficulty in obtaining the conversion enzyme, high price, and long reaction time.
[0009] Based on the above situation, it is necessary to develop a method with simple route, low manufacturing cost, high yield and purity, economic feasibility and suitable for industrial production. SUMMARY OF THE INVENTION
[0011] In a first aspect, the present application provides a recombinant genetically engineered bacterium for preparing nelarabine.
[0012] In a second aspect, the present application provides a microbial preparation comprising wet cells of the recombinant genetically engineered bacteria.
[0013] In a third aspect, the present application provides a bio-enzyme catalyst obtained by culturing recombinant genetically engineered bacteria, and a method for preparing nelarabine using the recombinant genetically engineered bacteria or the bio-enzyme catalyst.
[0014] In a fourth aspect, the present application provides a recombinant genetically engineered bacterium and a biological enzyme catalyst obtained by culturing the same for preparing nelarabine. Summary of the invention
[0015] In a first aspect, the present application provides a recombinant genetically engineered bacterium for preparing nelarabine.
[0016] The present application relates to a recombinant genetically engineered bacterium for preparing nelarabine, wherein the recombinant genetically engineered bacterium is an engineered bacterium Escherichia coli 7N04 (hereinafter referred to as "engineered bacterium 7N04" or "recombinant genetically engineered bacterium 7N04") containing genes for co-expressing uridine nucleoside phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase). The Chinese name is Escherichia coli (also referred to as "Escherichia coli" in this article), and the Latin name is Escherichia coli. It has been deposited in the China Center for Type Culture Collection designated by the State Intellectual Property Office of China on April 29, 2021, and the deposit address is Wuhan University, Wuhan, China, and the deposit number is: CCTCC No.M2021490. The recombinant genetically engineered bacterium of the present application is also called Escherichia coli BL21 (DE3) Plyss-PNPase-UPase.
[0017] In some embodiments, the present application relates to a recombinant genetic engineering bacterium (e.g., recombinant Escherichia coli), wherein the recombinant genetic engineering bacterium has a gene for co-expressing uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase) integrated into its genome. Alternatively, the recombinant genetic engineering bacterium comprises a recombinant plasmid containing a gene for co-expressing uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase). In some embodiments, the recombinant genetic engineering bacterium is Escherichia coli 7N04 having a gene for co-expressing uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase) integrated into its genome. Alternatively, in some embodiments, the recombinant genetic engineering bacterium is Escherichia coli 7N04 containing a recombinant plasmid containing a gene for co-expressing uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase).
[0018] In some embodiments, the recombinant genetically engineered bacteria 7N04 is characterized by: OD 600nm ≥3.0, the cell morphology is short rod-shaped, the bacterial morphology is relatively uniform, and the culture medium is turbid and brown-yellow.
[0019] In some embodiments, the recombinant genetically engineered bacteria 7N04 is characterized by: OD 600nm ≥9.0, the cell morphology is short rod-shaped, the bacterial morphology is relatively uniform, and the culture medium is turbid and brown-yellow.
[0020] In some embodiments, the recombinant genetically engineered bacteria 7N04 has kanamycin resistance. Alternatively, the recombinant genetically engineered bacteria 7N04 can express aminoglycoside phosphotransferase (APH(3')II enzyme). Alternatively, the recombinant genetically engineered bacteria 7N04 has a kanamycin resistance gene (Kan) integrated into its genome. Alternatively, the recombinant genetically engineered bacteria 7N04 contains a recombinant plasmid containing a kanamycin resistance gene. The kanamycin resistance gene is one of the commonly used selection marker genes in genetic engineering, and adding kanamycin to the culture medium can help screen out positive clones.
[0021] In some embodiments, the recombinant genetically engineered bacteria is in the form of wet cells, and the wet cells are obtained by the following method: inoculating the recombinant genetically engineered bacteria 7N04 with a preservation number of CCTCC No.M2021490, fermenting and culturing, and collecting the wet cells after the fermentation is terminated. Wherein, the ratio of uracil nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1 to 1:3. In some embodiments, the ratio of uracil nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1.5 to 1:2.5. In some embodiments, the uracil nucleoside phosphorylase activity in the wet cells is 750 to 800 U / mL wet cells, and the purine nucleoside phosphorylase activity is 1750 to 1850 U / mL wet cells.
[0022] In the second aspect, the present application provides a microbial preparation comprising the wet cells of the above-mentioned recombinant genetically engineered bacteria. In some schemes, the wet cells are obtained by the following method: inoculating the recombinant genetically engineered bacteria 7N04 with a preservation number of CCTCC No.M2021490, fermenting and culturing, and collecting the wet cells after the fermentation is terminated. Wherein, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the wet cells is 750 to 800 U / mL wet cells, and the purine nucleoside phosphorylase activity is 1750 to 1850 U / mL wet cells.
[0023] In a third aspect, the present application provides a bio-enzyme catalyst obtained by culturing a recombinant genetically engineered bacterium with a deposit number of CCTCC No. M2021490, and a method for preparing nelarabine using the recombinant genetically engineered bacterium or the bio-enzyme catalyst.
[0024] In some embodiments, the present application provides a bio-enzyme catalyst containing a crude enzyme solution, wherein the bio-enzyme catalyst is prepared by fermentation culture, high-pressure homogenization, and high-temperature impurity removal using the recombinant genetic engineering bacteria 7N04 with a preservation number of CCTCC No.M2021490.
[0025] In some embodiments, the present application provides a bio-enzyme catalyst, which comes from the fermentation culture of the recombinant genetic engineering bacteria 7N04 with a deposit number of CCTCC No.M2021490. In some embodiments, the present application provides a bio-enzyme catalyst, wherein the bio-enzyme catalyst is obtained by fermenting and culturing the recombinant genetic engineering bacteria 7N04 with a deposit number of CCTCC No.M2021490, collecting the bacterial cells by centrifugation, and then obtaining the obtained bacterial cells by high-pressure homogenization and high-temperature impurity removal. In some embodiments, the present application provides a bio-enzyme catalyst, wherein the bio-enzyme catalyst is obtained by fermenting and culturing the recombinant genetic engineering bacteria 7N04 with a deposit number of CCTCC No.M2021490, collecting the bacterial cells by centrifugation, and then resuspending the obtained bacterial cells in a phosphate buffer, and then high-pressure homogenizing at 600-1200 bar, and removing impurities by heating in a water bath. In some embodiments, the present application provides a bio-enzyme catalyst, wherein the bio-enzyme catalyst is obtained by fermenting and culturing the recombinant genetically engineered bacteria 7N04 with a deposit number of CCTCC No. M2021490, collecting the bacteria by centrifugation, and then resuspending the obtained bacteria in a phosphate buffer, high-pressure homogenizing at 600-1200 bar, and heating in a water bath (e.g., a 50-70°C water bath) to remove impurities. The activity of uridine nucleoside phosphorylase in the bio-enzyme catalyst is 100-6000U / mL of the bio-enzyme catalyst, and the activity of purine nucleoside phosphorylase is 200-12000U / mL of the bio-enzyme catalyst.
[0026] In some embodiments, the method for preparing the bio-enzyme catalyst comprises the following steps:
[0027] (1) inoculating the recombinant genetically engineered bacteria 7N04 with a deposit number of CCTCC No. M2021490, fermenting and culturing, inducing protein expression with an inducer during the fermentation process, and collecting the bacteria after the fermentation is terminated;
[0028] (2) The bacterial cells are resuspended in phosphate buffer and then homogenized under high pressure and impurities are removed at high temperature to obtain a bio-enzyme catalyst containing a crude enzyme solution.
[0029] In some embodiments, the inducing agent is isopropyl-β-D-thiogalactoside (IPTG) and / or lactose. In some embodiments, the inducing agent is IPTG.
[0030] In some embodiments, the crude enzyme solution is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the crude enzyme solution is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the crude enzyme solution is 800 to 900 U / mL crude enzyme solution, and the purine nucleoside phosphorylase activity is 1800 to 1900 U / mL crude enzyme solution.
[0031] In some embodiments, the bio-enzyme catalyst comprises an enzyme solution obtained by further concentrating or diluting a crude enzyme solution. In some embodiments, the bio-enzyme catalyst comprises a crude enzyme powder formed by further freeze-drying a crude enzyme solution. In some embodiments, the bio-enzyme catalyst comprises an immobilized enzyme formed by further combining a crude enzyme solution with an immobilized resin.
[0032] In some embodiments, the bioenzyme catalyst is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the bioenzyme catalyst is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the bioenzyme catalyst is 100 to 6000 U / mL bioenzyme catalyst, and the purine nucleoside phosphorylase activity is 200 to 12000 U / mL bioenzyme catalyst.
[0033] In some embodiments, the pressure of high pressure homogenization in the preparation method of the bio-enzyme catalyst is 600-1200 bar. In some embodiments, the pressure of high pressure homogenization in the preparation method is 800-1000 bar.
[0034] In some embodiments, the temperature of high-temperature impurity removal in the preparation method of the bio-enzyme catalyst is 50-70° C. In some embodiments, the high-temperature impurity removal in the preparation method is carried out in a water bath. In some embodiments, the high-temperature impurity removal in the preparation method is carried out under heating at 60° C. in a water bath.
[0035] In some embodiments, prior to the fermentation culture, primary seed culture and secondary seed culture are performed.
[0036] In some embodiments, a culture medium comprising the following components is used for primary seed culture and secondary seed culture: yeast extract, sodium chloride, glucose, yeast extract, corn steep liquor. For example, the culture medium is composed of (by weight): yeast extract 2%, sodium chloride 0.5%, glucose 0.1%, yeast extract 0.5%, corn steep liquor 0.5%, and the balance of water. Alternatively, in some embodiments, a culture medium comprising the following components is used for primary seed culture and secondary seed culture: yeast extract, sodium chloride, peptone. For example, the culture medium is composed of (by weight): peptone 1.0%, yeast extract 0.5%, sodium chloride 0.5%, and the balance of water.
[0037] In some embodiments, the pH of the culture medium of the primary seed culture and the secondary seed culture is adjusted to 6.8-8.0 (eg, 7.0-7.2) using a NaOH solution.
[0038] In some embodiments, the secondary seed culture with an OD of 9 or more is fermented. In some embodiments, the secondary seed culture with an OD of 9 or more is inoculated into the fermentation medium at an inoculum of 0.1% to 1% (eg, 0.5%) for the fermentation.
[0039] In some embodiments, the secondary seed culture with an OD of 3 or more is fermented. In some embodiments, the secondary seed culture with an OD of 3 or more is inoculated into the fermentation medium at an inoculum of 1% to 10% (eg, 5%) for the fermentation.
[0040] In some embodiments, the fermentation culture is carried out using a culture medium containing the following components: yeast extract, sodium chloride, glucose, yeast extract, corn steep liquor, and polyether defoamer. For example, the culture medium is composed of the following (by weight): yeast extract 4.0%, sodium chloride 0.5%, glucose 0.25%, yeast extract 0.5%, corn steep liquor 0.5%, polyether defoamer 0.02%, and the balance of water. Alternatively, in some embodiments, the fermentation culture is carried out using a culture medium containing the following components: citric acid monohydrate, potassium chloride, ammonium sulfate, sodium dihydrogen phosphate, disodium hydrogen phosphate, magnesium sulfate heptahydrate, calcium chloride, glycerol, trace element solution (citric acid monohydrate, calcium chloride dihydrate, zinc sulfate heptahydrate, manganese sulfate monohydrate, copper sulfate pentahydrate, cobalt chloride hexahydrate, ferric chloride hexahydrate, boric acid, sodium molybdate), and polyether defoamer. For example, the culture medium is composed of the following (by weight): 0.116% citric acid monohydrate, 0.403% potassium chloride, 5.2% ammonium sulfate, 5.0% sodium dihydrogen phosphate, 1.86% disodium hydrogen phosphate, 0.104% magnesium sulfate heptahydrate, 0.255% calcium chloride, 3.0% glycerol, 1.0% trace element solution (relative to the total amount of the trace element solution, it contains: 1.04% citric acid monohydrate, 0.522% calcium chloride dihydrate, 0.206% zinc sulfate heptahydrate, 0.406% manganese sulfate monohydrate, 0.811% copper sulfate pentahydrate, 0.36% cobalt chloride hexahydrate, 1.006% ferric chloride hexahydrate, 0.003% boric acid, 0.002% sodium molybdate), 0.02% polyether defoamer, and the remainder water.
[0041] In some embodiments, the pH of the fermentation medium is adjusted to 6.0-7.5 (eg, 6.5-7.0) using NaOH solution.
[0042] In some embodiments, the present application provides a method for preparing nelarabine through biotransformation using the bioenzyme catalyst.
[0043] In some embodiments, the preparation method of nelarabine comprises taking 2-amino-6-methoxypurine and uridine arabinoside as substrates, adding the bioenzyme catalyst, carrying out a biotransformation reaction in a phosphate buffer, and separating and purifying to obtain nelarabine.
[0044] In some embodiments, the present application provides a method for preparing nelarabine by biotransformation using the recombinant genetically engineered bacterium 7N04 with a deposit number of CCTCC No. M2021490 to co-express purine nucleoside phosphorylase and uridine nucleoside phosphorylase.
[0045] In some embodiments, the preparation method of nelarabine comprises first using the recombinant genetic engineering bacteria 7N04 with a deposit number of CCTCCNo.M2021490 to co-express purine nucleoside phosphorylase and uridine nucleoside phosphorylase to prepare a biological enzyme catalyst, then using 2-amino-6-methoxypurine and arabinuridine as substrates, adding the biological enzyme catalyst, carrying out a biotransformation reaction in a phosphate buffer, and separating and purifying to obtain nelarabine.
[0046] In some embodiments, the method for preparing nelarabine comprises the following steps:
[0047] (1) inoculating the recombinant genetically engineered bacteria 7N04 with a deposit number of CCTCC No. M2021490, fermenting and culturing, inducing protein expression with an inducer during the fermentation process, and collecting the bacteria after the fermentation is terminated;
[0048] (2) resuspending the bacterial cells in phosphate buffer, homogenizing under high pressure, and removing impurities at high temperature to obtain a bio-enzyme catalyst containing a crude enzyme solution;
[0049] (3) Using 2-amino-6-methoxypurine and uridine arabinoside as substrates, adding a bioenzyme catalyst to a phosphate buffer, carrying out a biotransformation reaction, and separating and purifying nelarabine.
[0050] In some embodiments, the initial pH of the fermentation culture in step (1) is adjusted to a pH value of 6.5 to 8.0 using a NaOH solution. In some embodiments, the initial pH of the fermentation culture in step (1) is adjusted to a pH value of 6.5 to 7.0 using a NaOH solution. In some embodiments, the initial pH of the fermentation culture in step (1) is adjusted to a pH value of 6.8 to 8.0 using a NaOH solution. In some embodiments, the initial pH of the fermentation culture in step (1) is adjusted to a pH value of 7.0 to 7.2 using a NaOH solution.
[0051] In some embodiments, the pH of the fermentation culture process in step (1) is 6.5 to 7.0. In some embodiments, the pH of the fermentation culture process in step (1) is 6.8 to 8.0. In some embodiments, the pH of the fermentation culture process is 7.5 to 7.6.
[0052] In some embodiments, the temperature of the fermentation culture process in step (1) is 30-40° C. In some embodiments, the temperature of the fermentation culture process is 30-37° C. In some embodiments, the temperature of the fermentation culture process is 35-37° C.
[0053] In some embodiments, the fermentation culture process in step (1) has a rotation speed of 100 to 1000 rpm. In some embodiments, the fermentation culture process in step (1) has a rotation speed of 200 to 700 rpm.
[0054] In some embodiments, the fermentation culture is carried out using a culture medium comprising the following components: yeast extract powder, sodium chloride, glucose, yeast extract, corn steep liquor, polyether defoamer. In some embodiments, the culture medium is adjusted to pH 6.8-8.0 (e.g., 7.0-7.2) with a NaOH solution before the fermentation culture is carried out.
[0055] In some embodiments, the fermentation culture is carried out using a culture medium containing the following components: citric acid monohydrate, potassium chloride, ammonium sulfate, sodium dihydrogen phosphate, sodium hydrogen phosphate, magnesium sulfate heptahydrate, calcium chloride, glycerol, trace element solution (citric acid monohydrate, calcium chloride dihydrate, zinc sulfate heptahydrate, manganese sulfate monohydrate, copper sulfate pentahydrate, cobalt chloride hexahydrate, ferric chloride hexahydrate, boric acid, sodium molybdate), and a polyether defoamer. In some embodiments, the culture medium is adjusted to pH 6.0 to 7.5 (e.g., 6.5 to 7.0) with a NaOH solution, and the fermentation culture is carried out.
[0056] In some embodiments, the inducer in step (1) includes but is not limited to isopropyl-β-D-thiogalactoside (IPTG) and lactose; in some embodiments, the inducer is IPTG.
[0057] In some embodiments, the fermentation culture process in step (1) also includes the culture of primary seeds and secondary seeds. In some embodiments, the pH of the culture process of primary seeds and secondary seeds is 6.8-8.0; in some embodiments, the pH of the culture process of primary seeds and secondary seeds is 7.0-7.2; in some embodiments, the temperature of the culture process of primary seeds and secondary seeds is 30-40°C; in some embodiments, the temperature of the culture process of primary seeds and secondary seeds is 35-37°C; in some embodiments, the rotation speed of the culture process of primary seeds and secondary seeds is 100-500 rpm; in some embodiments, the rotation speed of the culture process of primary seeds and secondary seeds is 200-300 rpm.
[0058] In some embodiments, the primary seed culture and the secondary seed culture are carried out using a culture medium containing the following components: yeast extract powder, sodium chloride, glucose, yeast extract, corn steep liquor. Alternatively, in some embodiments, the primary seed culture and the secondary seed culture are carried out using a culture medium containing the following components: yeast extract powder, sodium chloride, peptone. In some embodiments, the pH of the culture medium for the primary seed culture and the secondary seed culture is adjusted to 6.8 to 8.0 (e.g., 7.0 to 7.2) with a NaOH solution.
[0059] In some embodiments, the secondary seed culture with an OD of 9 or more is fermented. In some embodiments, the secondary seed culture with an OD of 9 or more is inoculated into the fermentation medium at an inoculum of 0.1% to 1% (eg, 0.5%) for the fermentation.
[0060] In some embodiments, the secondary seed culture with an OD of 3 or more is fermented. In some embodiments, the secondary seed culture with an OD of 3 or more is inoculated into the fermentation medium at an inoculum of 1% to 10% (eg, 5%) for the fermentation.
[0061] In some embodiments, the fermentation culture process in step (1) further includes a process of sterilizing the culture medium.
[0062] In some embodiments, step (1) collects the bacteria by centrifugation. In some embodiments, the centrifugation speed is 4000-5000 rpm. In some embodiments, the centrifugation time is 10-30 minutes; in some embodiments, the centrifugation time is 15-20 minutes.
[0063] In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the crude enzyme solution of step (2) is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the crude enzyme solution of step (2) is 1:1.5 to 1:2.5.
[0064] In some embodiments, the crude enzyme solution is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the crude enzyme solution is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the crude enzyme solution is 800 to 900 U / mL crude enzyme solution, and the purine nucleoside phosphorylase activity is 1800 to 1900 U / mL crude enzyme solution.
[0065] In some embodiments, the biological enzyme catalyst of step (2) includes an enzyme liquid obtained by further concentrating or diluting a crude enzyme liquid. In some embodiments, the biological enzyme catalyst of step (2) includes a crude enzyme powder formed by further freeze-drying the crude enzyme liquid. In some embodiments, the biological enzyme catalyst of step (2) includes an immobilized enzyme formed by further combining the crude enzyme liquid with an immobilized resin. In some embodiments, the biological enzyme catalyst of step (2) includes an immobilized enzyme obtained by mixing a crude enzyme liquid with an epoxy resin.
[0066] In some embodiments, the bioenzyme catalyst is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the bioenzyme catalyst is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the bioenzyme catalyst is 100 to 6000 U / mL bioenzyme catalyst, and the purine nucleoside phosphorylase activity is 200 to 12000 U / mL bioenzyme catalyst.
[0067] In some embodiments, the bioenzyme catalyst for preparing nelarabine is characterized in that the purine nucleoside phosphorylase activity is 200-4000 U / mL, and the bioconversion rate is above 75%, preferably above 80%.
[0068] In some embodiments, the bioenzyme catalyst for preparing nelarabine is characterized in that the purine nucleoside phosphorylase activity is 200-4000 U / mL and the bioconversion rate is above 90%.
[0069] In some embodiments, the pressure of high pressure homogenization in step (2) is 600-1200 bar. In some embodiments, the pressure of high pressure homogenization in step (2) is 800-1000 bar.
[0070] In some embodiments, the temperature of high temperature impurity removal in step (2) is 50-70° C. In some embodiments, the high temperature impurity removal in step (2) is carried out in a water bath. In some embodiments, the high temperature impurity removal in step (2) is carried out under heating at 60° C. in a water bath.
[0071] In some embodiments, the phosphate buffer in steps (2) and (3) includes but is not limited to solutions of dihydrogen phosphate and its conjugate base dihydrogen phosphate; in some embodiments, the phosphate ions in the phosphate buffer in steps (2) and (3) include phosphate ions produced by aqueous solutions of the following salts: monosodium dihydrogen phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, diammonium hydrogen phosphate, and ammonium dihydrogen phosphate; in some embodiments, the phosphate buffer is a solution of dipotassium hydrogen phosphate and potassium dihydrogen phosphate.
[0072] In some embodiments, the pH of the phosphate buffer in steps (2) and (3) is 6.0 to 8.0, such as 6.5 to 8.0 or 6.8 to 8.0; in some embodiments, the pH of the phosphate buffer is 7.0 to 7.2.
[0073] In some embodiments, the weight ratio of the bacteria to the phosphate buffer in step (2) is 1:5 to 1:10; in some embodiments, the weight ratio of the bacteria to the phosphate buffer in step (2) is 1:9.
[0074] In some embodiments, the reaction temperature in step (3) is 50-85°C; in some embodiments, the reaction temperature in step (3) is 50-60°C; in some embodiments, the reaction temperature in step (3) is 55-60°C.
[0075] In some embodiments, the reaction speed in step (3) is 60 to 500 rpm; in some embodiments, the reaction speed in step (3) is 90 to 300 rpm; in some embodiments, the reaction speed in step (3) is 100 to 180 rpm.
[0076] In some embodiments, the concentration of 2-amino-6-methoxypurine in step (3) is 5 to 35 g / L; in some embodiments, the concentration of 2-amino-6-methoxypurine in step (3) is 6 to 15 g / L, for example, 8 to 13 g / L; in some embodiments, the concentration of 2-amino-6-methoxypurine in step (3) is 13 g / L; in some embodiments, the concentration of 2-amino-6-methoxypurine in step (3) is 8 g / L.
[0077] In some embodiments, the concentration of arabinuridine in step (3) is 10-70 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 13-65 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 13-65 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 14-50 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 15-35 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 16-26 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 16 g / L; in some embodiments, the concentration of arabinuridine in step (3) is 26 g / L.
[0078] In some embodiments, the molar ratio of the feeding amount of the substrate 2-amino-6-methoxypurine to arabinuridine is 1:1 to 1:3; in some embodiments, the molar ratio of the feeding amount of the substrate 2-amino-6-methoxypurine to arabinuridine is 1:1.2 to 1:2; in some embodiments, the molar ratio of the feeding amount of the substrate 2-amino-6-methoxypurine to arabinuridine is 1:1.6.
[0079] In some embodiments, the bioenzyme catalyst in step (3) is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the bioenzyme catalyst is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the bioenzyme catalyst is 1:1.5 to 1:2.5.
[0080] In some embodiments, the bio-enzyme catalyst in step (3) is characterized in that the purine nucleoside phosphorylase activity is 200-4000 U / mL and the bioconversion rate is above 75%.
[0081] In some embodiments, the bio-enzyme catalyst in step (3) is characterized in that the purine nucleoside phosphorylase activity is 200-4000 U / mL and the bioconversion rate is above 90%.
[0082] In some embodiments, in the bioconversion reaction of step (3), when the activity of purine nucleoside phosphorylase is 2000U-4000U / mL, the conversion rate reaches more than 90% after 3-6 hours of reaction.
[0083] In some embodiments, in the bioconversion reaction of step (3), when the activity of purine nucleoside phosphorylase is 3000 U / mL, the conversion rate reaches more than 95% after 3 hours of reaction.
[0084] In some embodiments, in the bioconversion reaction of step (3), when the activity of purine nucleoside phosphorylase is 400U-1000U / mL, the conversion rate reaches more than 75% after 24-48 hours of reaction.
[0085] In some embodiments, in the bioconversion reaction of step (3), when the activity of purine nucleoside phosphorylase is 400U-1000U / mL, the conversion rate reaches more than 90% after 24-48 hours of reaction.
[0086] In some embodiments, in the bioconversion reaction of step (3), when the activity of purine nucleoside phosphorylase is 400 U / mL, the conversion rate reaches more than 75% after 24 hours of reaction.
[0087] In some embodiments, in the bioconversion reaction of step (3), when the activity of purine nucleoside phosphorylase is 600 U / mL, the conversion rate reaches more than 95% after 24 to 48 hours of reaction.
[0088] In some embodiments, the separation and purification process in step (3) includes but is not limited to conversion solution pretreatment, column chromatography, concentration, crystallization, and drying. In some embodiments, if necessary, the nelarabine separated and purified in step (3) can be refined by recrystallization.
[0089] In some embodiments, the organic solvent used in the separation and purification process in step (3) includes but is not limited to methanol and / or ethanol and / or acetone. In some embodiments, the organic solvent used in the separation and purification process in step (3) is ethanol.
[0090] In a fourth aspect, the present application provides a recombinant genetically engineered bacterium with a deposit number of CCTCC No. M2021490, a biological enzyme catalyst obtained by its culture, and a microbial preparation containing its wet bacteria for use in preparing nelarabine.
[0091] In some embodiments, the recombinant genetic engineering bacteria is an engineering bacteria 7N04 containing genes for co-expressing uridine nucleoside phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase). Alternatively, the recombinant genetic engineering bacteria is an engineering bacteria 7N04 having genes for co-expressing uridine nucleoside phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase) integrated into its genome. Alternatively, the recombinant genetic engineering bacteria is an engineering bacteria 7N04 containing a recombinant plasmid containing genes for co-expressing uridine nucleoside phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase).
[0092] In some embodiments, the recombinant genetically engineered bacteria are: inoculated with the recombinant genetically engineered bacteria 7N04 with a preservation number of CCTCCNo.M2021490, fermented and cultured, and the wet cells collected after the fermentation is terminated, wherein the ratio of uracil nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1 to 1:3. In some embodiments, the ratio of uracil nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1.5 to 1:2.5. In some embodiments, the uracil nucleoside phosphorylase activity in the wet cells is 750 to 800 U / mL wet cells, and the purine nucleoside phosphorylase activity is 1750 to 1850 U / mL wet cells.
[0093] In some embodiments, the biological enzyme catalyst is characterized in that it contains a crude enzyme solution prepared by fermentation culture, high pressure homogenization, and high temperature impurity removal using the recombinant genetic engineering bacteria 7N04 with a deposit number of CCTCCNo.M2021490. In some embodiments, the biological enzyme catalyst includes an enzyme solution obtained by further concentrating or diluting the crude enzyme solution. In some embodiments, the biological enzyme catalyst includes a crude enzyme powder formed by further freeze-drying the crude enzyme solution. In some embodiments, the biological enzyme catalyst includes an immobilized enzyme formed by further combining the crude enzyme solution with an immobilized resin.
[0094] In some embodiments, the crude enzyme solution is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the crude enzyme solution is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the crude enzyme solution is 800 to 900 U / mL crude enzyme solution, and the purine nucleoside phosphorylase activity is 1800 to 1900 U / mL crude enzyme solution.
[0095] In some embodiments, the bioenzyme catalyst is characterized in that the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity is 1:1 to 1:3. In some embodiments, the ratio of uridine phosphorylase activity to purine nucleoside phosphorylase activity in the bioenzyme catalyst is 1:1.5 to 1:2.5. In some embodiments, the uridine phosphorylase activity in the bioenzyme catalyst is 100 to 6000 U / mL bioenzyme catalyst, and the purine nucleoside phosphorylase activity is 200 to 12000 U / mL bioenzyme catalyst.
[0096] In some embodiments, the bioenzyme catalyst for preparing nelarabine is characterized in that the purine nucleoside phosphorylase activity is 200-4000 U / mL and the bioconversion rate is above 75%.
[0097] In some embodiments, the bioenzyme catalyst for preparing nelarabine is characterized in that the purine nucleoside phosphorylase activity is 200-4000 U / mL and the bioconversion rate is above 90%.
[0098] In some embodiments, the bioenzyme catalyst is used for the bioconversion reaction of preparing nelarabine, and when the activity of purine nucleoside phosphorylase is 2000U-4000U / mL, the conversion rate reaches more than 90% after 3-6 hours of reaction.
[0099] In some embodiments, the bioenzyme catalyst is used for the bioconversion reaction of preparing nelarabine, and when the activity of purine nucleoside phosphorylase is 3000 U / mL, the conversion rate reaches more than 95% after 3 hours of reaction.
[0100] In some embodiments, the bioenzyme catalyst is used for the bioconversion reaction of preparing nelarabine, and when the activity of purine nucleoside phosphorylase is 400U-1000U / mL, the conversion rate reaches more than 75% after 24-48 hours of reaction.
[0101] In some embodiments, the bioenzyme catalyst is used for the bioconversion reaction of preparing nelarabine, and when the activity of purine nucleoside phosphorylase is 400U-1000U / mL, the conversion rate reaches more than 90% after 24-48 hours of reaction.
[0102] In some embodiments, the bioenzyme catalyst is used for the bioconversion reaction of preparing nelarabine, and when the activity of purine nucleoside phosphorylase is 400 U / mL, the conversion rate reaches more than 75% after 24 hours of reaction.
[0103] In some embodiments, the bioenzyme catalyst is used for the bioconversion reaction of preparing nelarabine, and when the activity of purine nucleoside phosphorylase is 600 U / mL, the conversion rate reaches more than 95% after 24 to 48 hours of reaction.
[0104] The present application uses recombinant genetically engineered bacteria 7N04 as a new enzyme source for synthesizing nelarabine. The enzyme-catalyzed reaction requires only one step of reaction, with a short catalytic time and a high bioconversion rate. Compared with the wild enzyme expressed by the artificially mutated Escherichia coli strain, the enzyme solution requirement is reduced by 20 to 40 times, the enzyme activity of the enzyme solution is increased by 10 to 400 times, the bioconversion reaction time is reduced from 5 to 6 days to 1 to 2 days, the conversion rate of nelarabine is increased from 40 to 50% to more than 90%, and the reaction solution volume is reduced by 2 to 4 times. The substrate utilization rate is high and the enzyme activity is highly stable. In addition, the present application uses recombinant genetically engineered bacteria 7N04 to catalyze the synthesis of nelarabine, which has the advantage of achieving a high conversion rate (≥95%) in a short time (3 hours). The entire preparation process of nelarabine biotransformation uses only ethanol as a solvent, has little pollution to the environment, mild conditions, simple operating procedures, short production cycle, and significantly increased yield. The methods for residual detection, protein detection and other experiments of later products are easy to develop, the equipment requirements are not high, and the production cost is low. It is an economically feasible preparation method suitable for industrial production.
[0105] Herein, unless otherwise specified, the terms "comprise, comprises and comprising" or their equivalents (e.g., contain, containing, include, including) are open-ended expressions and should be understood as "including but not limited to", meaning that in addition to the listed elements, components and steps, other unspecified elements, components and steps may also be included.
[0106] As used herein, unless otherwise indicated, the terms "polynucleotide", "nucleic acid", "nucleic acid sequence" and "gene" are used interchangeably to refer to a product formed by two or more nucleotides linked by phosphodiester bonds.
[0107] In this article, unless otherwise specified, the parameter values used herein should be understood to be modified by the term "about" in all cases. For example, when connected with a percentage, the term "about" can mean, for example, there is a change of ±0.1%, preferably ±0.05%, and more preferably ±0.01% relative to the value it modifies.
[0108] Unless the context clearly indicates otherwise, singular terms include plural referents and vice versa. Similarly, the word "or" is intended to include "and" and vice versa unless the context clearly indicates otherwise.
[0109] Herein, unless otherwise indicated, the terms "recombinant plasmid" and "recombinant expression vector" are used interchangeably. DETAILED DESCRIPTION
[0110] The technical solution of the present application is described with specific examples, but the protection scope of the present application is not limited to the following examples. The reagents and reference substances used are all commercially available products. Unless otherwise specified, the consumables and instruments used in the following examples are all commercially available.
[0111] In this application, "wet bacteria", "crude enzyme solution", "biological enzyme catalyst" and the like are used as samples to be tested, and the specific operation of the method for determining the uridine nucleoside phosphorylase activity and the purine nucleoside phosphorylase activity is as follows:
[0112]
Uridine phosphorylase activity assay method
[0113] Solution A: Weigh 22.8 g of dipotassium hydrogen phosphate trihydrate, add 1000 mL of water to dissolve it, and obtain a 0.1 mol / L dipotassium hydrogen phosphate solution; weigh 13.6 g of anhydrous potassium dihydrogen phosphate, add 1000 mL of water to dissolve it, and obtain a 0.1 mol / L potassium dihydrogen phosphate solution; use the above 0.1 mol / L potassium dihydrogen phosphate solution to adjust the pH value of the 0.1 mol / L dipotassium hydrogen phosphate solution to 7.0, and obtain solution A (0.1 mol / L phosphate solution, pH 7.0).
[0114] Uracil reference solution Take about 25 mg of reference uracil, accurately weigh it, place it in a 250 mL volumetric flask, add an appropriate amount of solution A, sonicate for 3 minutes to dissolve it, dilute to the scale with solution A, shake well, accurately measure 1 mL, place it in a 25 mL volumetric flask, dilute to the scale with solution A, and shake well.
[0115] Substrate solution: Take about 488 mg of uridine arabinoside, accurately weigh it, put it in a 50 mL penicillin bottle, accurately add 20 mL of solution A, add a rotor, put it in a magnetic stirring water bath pot at 60 ° C water bath preheating for 10 minutes, add 1 mL of solution A, react at 60 ° C while stirring for 30 minutes, take it out, immediately add 400 μL of 6 mol / L hydrochloric acid solution, shake well, filter with 0.22 μm filter membrane, and take the filtrate to obtain.
[0116] Accurately measure 1 mL of the sample to be tested, place it in a 50 mL volumetric flask, dilute it to the mark with solution A, shake well, accurately transfer 1 mL, place it in a 10 mL volumetric flask, dilute it to the mark with solution A, and shake well.
[0117] Take about 488 mg of uridine arabinoside for the test solution, accurately weigh it, put it in a 50 mL penicillin bottle, accurately add 20 mL of solution A, add a rotor, put it in a magnetic stirring water bath pot at 60 ℃ water bath for preheating for 10 minutes, add 1 mL of enzyme stock solution, react at 60 ℃ while stirring for 30 minutes, take it out, immediately add 400 μL of 6 mol / L hydrochloric acid solution, shake well, filter with a 0.22 μm filter membrane, and take the filtrate to obtain.
[0118] For blank solution, accurately transfer 20 mL of solution A into a 50 mL penicillin bottle, add a rotor, and preheat in a magnetic stirring water bath at 60°C for 10 minutes. Then, add 1 mL of the above enzyme stock solution, react at 60°C with stirring for 30 minutes, take out, immediately add 400 μL of 6 mol / L hydrochloric acid solution, shake well, cool, filter with a 0.22 μm filter membrane, and obtain the filtrate.
[0119] Chromatographic conditions: Octadecylsilane bonded silica gel was used as filler (Waters Atlantis TM T3 column 4.6mm×150mm, 3μm or chromatographic column with equivalent performance); 0.1vol% trifluoroacetic acid in water as mobile phase A, 0.1vol% trifluoroacetic acid in acetonitrile as mobile phase B, linear gradient elution as shown in the table below; flow rate 1.0mL per minute; detection wavelength 258nm; column temperature 30℃; injection volume 10μL.
[0120]
[0121]
[0122] Determination method: Accurately measure the uracil reference solution, substrate solution, test solution and blank solution, inject them into the liquid chromatograph respectively, record the chromatogram, and calculate the potency according to the following formula.
[0123]
[0124]
[0125] Where:
[0126] A i : The peak area of uracil in the test solution;
[0127] A0: peak area of uracil in blank solution;
[0128] A 底 : The peak area of uracil in the substrate solution;
[0129] A 对 : The peak area of uracil in the uracil reference solution;
[0130] C 对 : The concentration of uracil in the uracil reference solution (mg / mL);
[0131] n: dilution factor of enzyme stock solution;
[0132] M: molar mass of uracil (112.09);
[0133] f 均值 : the mean value of f.
[0134] Definition of potency unit: Under the above conditions, the amount of enzyme required to catalyze uridine arabinoside to produce 1 μmol of uracil per minute is 1 unit of uridine nucleoside phosphorylase activity.
[0135] Purine nucleoside phosphorylase activity assay method
[0136] Solution A: Weigh 22.8 g of dipotassium hydrogen phosphate trihydrate, add 1000 mL of water to dissolve it, and obtain 0.1 mol / L dipotassium hydrogen phosphate solution; weigh 13.6 g of anhydrous potassium dihydrogen phosphate, add 1000 mL of water to dissolve it, and obtain 0.1 mol / L potassium dihydrogen phosphate solution; use the above 0.1 mol / L potassium dihydrogen phosphate solution to adjust the pH value of 0.1 mol / L dipotassium hydrogen phosphate solution to 7.0, and obtain solution A (0.1 mol / L potassium phosphate solution, pH 7.0).
[0137] Hypoxanthine reference solution Take about 25 mg of reference hypoxanthine, accurately weigh it, place it in a 100 mL volumetric flask, add an appropriate amount of solution A, sonicate for 3 minutes to dissolve it, dilute it to the scale with solution A, shake well, accurately measure 1 mL, place it in a 20 mL volumetric flask, dilute it to the scale with solution A, and shake well.
[0138] Substrate solution: Take about 536 mg of inosine, accurately weigh it, put it in a 50 mL penicillin bottle, accurately add 20 mL of solution A, add a rotor, put it in a magnetic stirring water bath and preheat it at 60 ° C for 10 minutes, then add 1 mL of solution A, react while stirring at 60 ° C for 30 minutes, take it out, immediately add 3 mL of 10 mol / L sodium hydroxide solution, shake quickly, then add 4.5 mL of 6 mol / L hydrochloric acid solution, shake well, cool, filter with a 0.22 μm filter membrane, and take the filtrate to obtain.
[0139] Accurately measure 1 mL of the sample to be tested from the enzyme stock solution, place it in a 200 mL volumetric flask, dilute to the mark with solution A, and shake well.
[0140] Test solution: Take about 536 mg of inosine, accurately weigh it, put it in a 50 mL penicillin bottle, accurately add 20 mL of solution A, add a rotor, put it in a magnetic stirring water bath and preheat it at 60 ° C for 10 minutes, then add 0.1 mL of enzyme stock solution, react while stirring at 60 ° C for 30 minutes, take it out, immediately add 3 mL of 10 mol / L sodium hydroxide solution, shake quickly, then add 4.5 mL of 6 mol / L hydrochloric acid solution, shake well, cool, filter with a 0.22 μm filter membrane, and take the filtrate to obtain.
[0141] For blank solution, accurately transfer 20 mL of solution A into a 50 mL penicillin bottle, add a rotor, and preheat in a magnetic stirring water bath at 60°C for 10 minutes. Then, add 0.1 mL of the above enzyme stock solution, react at 60°C with stirring for 30 minutes, take out, immediately add 3 mL of 10 mol / L sodium hydroxide solution, shake quickly, then add 4.5 mL of 6 mol / L hydrochloric acid solution, shake well, filter with a 0.22 μm filter membrane, and obtain the filtrate.
[0142] Chromatographic conditions: Octadecylsilane bonded silica gel was used as filler (Waters Atlantis TM T3 column 4.6mm×150mm, 3μm or chromatographic column with equivalent performance); 0.1vol% trifluoroacetic acid in water as mobile phase A, 0.1vol% trifluoroacetic acid in acetonitrile as mobile phase B, linear gradient elution as shown in the table below; flow rate 1.0mL per minute; detection wavelength 249nm; column temperature 30℃; injection chamber temperature 10℃; injection volume 10μL.
[0143]
[0144] Determination method: Accurately measure the hypoxanthine reference solution, substrate solution, test solution and blank solution, inject them into the liquid chromatograph respectively, record the chromatogram, and calculate the potency according to the following formula.
[0145]
[0146]
[0147] Where:
[0148] A i : Peak area of hypoxanthine in the test solution;
[0149] A0: peak area of hypoxanthine in blank solution;
[0150] A 底 : peak area of hypoxanthine in substrate solution;
[0151] A 对 : Peak area of hypoxanthine in hypoxanthine reference solution;
[0152] C 对 : The concentration of hypoxanthine in the hypoxanthine reference solution (mg / mL);
[0153] n: dilution factor of enzyme stock solution;
[0154] M: molar mass of hypoxanthine (136.11);
[0155] f 均值 : the mean value of f.
[0156] Definition of potency unit: Under the above conditions, the amount of enzyme required to catalyze the production of 1 μmol of hypoxanthine from inosine per minute is 1 unit of purine nucleoside phosphorylase activity.
[0157] Example 1: Preparation of crude enzyme solution
[0158] Use an inoculation needle to dip a small amount of bacterial liquid from the glycerol tube of the recombinant genetically engineered bacteria 7N04 with a preservation number of CCTCC No.M2021490, adopt secondary fermentation, use the shake flask seed liquid as the primary seed liquid, and then connect it to a 50L secondary fermentation tank. After the fermentation is terminated, the bacteria are collected by centrifugation and washed.
[0159] 1.1 Shake flask primary seed preparation
[0160] (1) Culture medium ingredients: 2% yeast extract powder, 0.5% sodium chloride, 0.1% glucose, 0.5% yeast extract, 0.5% corn steep liquor, and the balance water.
[0161] (2) Preparation and cultivation
[0162] Use NaOH solution to adjust the pH value of the culture medium to 7.0-7.2. Divide the above culture medium into 500mL Erlenmeyer flasks, with a filling volume of 100mL. Sterilize at 121℃ for 30 minutes. Inoculation amount 0.1%, culture temperature: 35℃, rotation speed: 220-230rpm, culture time: 9-10 hours. When transplanting after culture, OD is greater than or equal to 9, and it can be connected to the secondary seed tank only after confirming that there is no contamination.
[0163] (3) Seed transplanting standards
[0164]
[0165]
[0166] 1.2 Secondary seed preparation
[0167] (1) Culture medium ingredients: 2% yeast extract powder, 0.5% sodium chloride, 0.1% glucose, 0.5% yeast extract, 0.5% corn steep liquor, and the balance water.
[0168] (2) Preparation and cultivation
[0169] Adjust the pH value of the culture medium to 7.0-7.2 with NaOH solution. Sterilize at 121℃ for 30 minutes. Inoculation amount 0.5%, culture temperature: 35℃, rotation speed: 220-230rpm, culture time: 3-5 hours. When transplanting after culture, OD is greater than or equal to 9, and it can be connected to the fermentation tank only after confirming that there is no contamination.
[0170] (3) Seed transplanting standards
[0171] project Control requirements Appearance Turbid, brownish yellow <![CDATA[OD 600nm ]]> ≥9.0 Microscopic examination Short rod-shaped, relatively uniform bacterial morphology
[0172] 1.3 Fermentation tank fermentation process
[0173] (1) Culture medium ingredients: 4.0% yeast extract powder, 0.5% sodium chloride, 0.25% glucose, 0.5% yeast extract, 0.5% corn steep liquor, 0.02% polyether defoamer (purchased from Jiangsu Sterek Chemical Co., Ltd.), and the balance water.
[0174] (2) Preparation
[0175] Weigh various culture medium components into a batching bucket, add water and stir to dissolve, then transfer to a fermentation tank, adjust the pH value of the culture medium to 7.0-7.2 with NaOH solution, and then sterilize at 121-125°C for 30 minutes.
[0176] (3) Fermentation tank culture process conditions
[0177] project index Inoculation volume 0.5% Cultivation temperature 35℃ Tank pressure 0.04~0.06MPa Speed 200~700 rpm Ventilation 1.0~2.0v / v / m Dissolved oxygen ≥30% Cultivation time 8-10 hours pH Control 50% glucose was added to control the pH value within the range of 7.5 to 7.6.
[0178] During the fermentation process, 0.05-0.2 mmol / L isopropyl-β-D-thiogalactoside was used to induce the culture.
[0179] (4) Tank release index
[0180] project Control requirements Appearance Turbid, brown Wet cell concentration ≥12%
[0181] 1.4 Collecting bacteria
[0182] After the fermentation is terminated, the cells are collected by centrifugation at 4500 rpm for 15 to 20 minutes and then washed once with an appropriate amount of distilled water.
[0183] 1.5 Preparation of crude enzyme solution
[0184] A 0.05 mol / L potassium dihydrogen phosphate solution was prepared as a buffer in a reactor, and the pH was adjusted to 7.0 with a 0.05 mol / L potassium dihydrogen phosphate solution. The bacterial cells and the buffer were resuspended in a weight ratio of 1:9, homogenized under a pressure of 800-1000 bar, and part of the impurities were removed in a 60°C water bath to obtain a crude enzyme solution.
[0185] Example 2: Preparation of crude enzyme solution
[0186] Use an inoculation needle to dip a small amount of bacterial liquid from the glycerol tube of the recombinant genetically engineered bacteria 7N04 with a preservation number of CCTCC No.M2021490, adopt secondary fermentation, use the shake flask seed liquid as the primary seed liquid, and then connect it to a 50L secondary fermentation tank. After the fermentation is terminated, the bacteria are collected by centrifugation and washed.
[0187] 2.1 Shake flask primary seed preparation
[0188] (1) Medium ingredients: 1.0% peptone, 0.5% yeast extract powder, 0.5% sodium chloride, and the balance water.
[0189] (2) Preparation and cultivation
[0190] The above culture medium was divided into 500ml Erlenmeyer flasks, with a filling volume of 100ml. Sterilize at 121℃ for 30 minutes. Inoculation amount 0.1%, culture temperature: 37℃, rotation speed: 220-230rpm, culture time: 6-10 hours. When transplanting after culture, OD≥3.0, and it can be connected to the secondary fermentation tank only after confirming that there is no contamination.
[0191] (3) Seed transplanting standards
[0192] project Control requirements Appearance Turbid, brownish yellow <![CDATA[OD 600nm ]]> ≥3.0 Microscopic examination Short rod-shaped, relatively uniform bacterial morphology
[0193] 2.2 Secondary seed preparation
[0194] (1) Medium ingredients: 1.0% peptone, 0.5% yeast extract powder, 0.5% sodium chloride, and the balance water.
[0195] (2) Preparation and cultivation
[0196] The above culture medium was divided into 500ml Erlenmeyer flasks, with a filling volume of 100ml. Sterilize at 121℃ for 30 minutes. Inoculation amount 0.1%, culture temperature: 37℃, rotation speed: 220-230rpm, culture time: 6-10 hours. When transplanting after culture, OD≥3.0, and it can be connected to the secondary fermentation tank only after confirming that there is no contamination.
[0197] (3) Seed transplanting standards
[0198] project Control requirements Appearance Turbid, brownish yellow <![CDATA[OD 600nm ]]> ≥3.0 Microscopic examination Short rod-shaped, relatively uniform bacterial morphology
[0199] 2.3 Fermentation process in fermenter
[0200] (1) Culture medium ingredients: 0.116% citric acid monohydrate, 0.403% potassium chloride, 5.2% ammonium sulfate, 5.0% sodium dihydrogen phosphate, 1.86% disodium hydrogen phosphate, 0.104% magnesium sulfate heptahydrate, 0.255% calcium chloride, 3.0% glycerol, 1.0% trace element solution (relative to the total amount of the trace element solution, including: 1.04% citric acid monohydrate, 0.522% calcium chloride dihydrate, 0.206% zinc sulfate heptahydrate, 0.406% manganese sulfate monohydrate, 0.811% copper sulfate pentahydrate, 0.36% cobalt chloride hexahydrate, 1.006% ferric chloride hexahydrate, 0.003% boric acid, 0.002% sodium molybdate), 0.02% polyether defoamer, and the balance water.
[0201] (2) Preparation
[0202] Weigh various culture medium components into a batching bucket, add water and stir to dissolve, then transfer to a fermentation tank, adjust the pH value of the culture medium to 6.5-7.0 with NaOH solution, and then sterilize at 121-125°C for 30 minutes.
[0203] (3) Fermentation tank culture process conditions
[0204]
[0205]
[0206] During the fermentation process, 0.05-0.2 mmol / L isopropyl-β-D-thiogalactoside was used to induce the culture.
[0207] (4) Tank release index
[0208] project Control requirements Appearance Turbid, brownish yellow Wet cell concentration ≥15%
[0209] 2.4 Collecting bacteria
[0210] After the fermentation is terminated, the cells are collected by centrifugation at 4500 rpm for 15 to 20 minutes and then washed once with an appropriate amount of distilled water.
[0211] 2.5 Preparation of crude enzyme solution
[0212] A 0.05 mol / L potassium dihydrogen phosphate solution was prepared as a buffer in the reactor, and the pH was adjusted to 7.0 with a 0.05 mol / L potassium dihydrogen phosphate solution. The bacterial cells and the buffer were resuspended in a weight ratio of 1:9, homogenized under a pressure of 800-1000 bar, and part of the impurities were removed in a 60°C water bath to obtain a crude enzyme solution.
[0213] Example 3: Preparation of Nelarabine
[0214] In a reaction kettle, the pH is adjusted to 7.0 with 0.05 mol / L potassium dihydrogen phosphate solution, 8 g / L of substrate 2-amino-6-methoxypurine and 16 g / L of urarabinoside are added, the temperature is raised to 50-60°C for dissolution, the temperature of the resulting liquid is controlled at 55°C, a crude enzyme solution with an activity of 3000 U / mL of purine nucleoside phosphorylase is added, and a bioconversion reaction is carried out at a rotation speed of 100-180 rpm. The reaction is carried out for about 3 hours, the reaction reaches equilibrium, and the conversion rate reaches 95.5%.
[0215] The reaction solution was allowed to settle, and the pH value was adjusted to 4.5 after the supernatant was collected by centrifugation. The solid was washed with distilled water, filtered by suction, and centrifuged to obtain a solid. The supernatant and filtrate obtained by centrifugation were combined, and the resulting liquid was passed through a macroporous resin column at a speed of 9 to 12 mL / min for adsorption on the column (1 g sample / 60 mL resin). After the adsorption was completed, it was washed with deionized water with a pH value of 10.84 (adjusting the pH value with ammonia water) of 6 times the volume of the resin, and then analyzed with 20% ethanol of 6 times the volume of the resin. The analytical solution was concentrated by vacuum decompression at 50 to 55°C by about 18 to 20 times, then cooled to room temperature, and then crystallized at a low temperature of 4 to 6°C, stirred for about 12 hours for crystallization, filtered, and vacuum dried at 50°C for 3 to 4 hours to obtain a crude product of nelarabine with a yield of 85%.
[0216] The crude nelarabine was recrystallized with anhydrous methanol at 60°C to obtain nelarabine crystalline powder, which was filtered and dried to obtain the finished nelarabine with an HPLC purity of more than 98% and a yield of 80%.
[0217] Example 4: Preparation of Nelarabine
[0218] In a reaction kettle, the pH is adjusted to 7.0 with 0.05 mol / L potassium dihydrogen phosphate solution, 13 g / L of substrate 2-amino-6-methoxypurine and 26 g / L of urarabinoside are added, the temperature is raised to 50-60°C for dissolution, the temperature of the resulting feed solution is controlled at 55°C, a crude enzyme solution with an activity of 600 U / mL of purine nucleoside phosphorylase is added, and a bioconversion reaction is carried out at a rotation speed of 100-180 rpm. The reaction is carried out for about 24-48 hours, the reaction reaches equilibrium, and the conversion rate reaches 95.6%.
[0219] The reaction solution was allowed to settle, and the pH value was adjusted to 4.5 after the supernatant was collected by centrifugation. The solid was washed with distilled water, filtered by suction, and centrifuged to obtain a solid. The supernatant and filtrate obtained by centrifugation were combined, and the resulting liquid was adsorbed on a macroporous resin column at a speed of 9 to 12 mL / min (1 g sample / 60 mL resin). After the adsorption was completed, it was washed with deionized water with a pH value of 10.84 (adjusting the pH value with ammonia water) of 6 times the volume of the resin, and then analyzed with 20% ethanol of 6 times the volume of the resin. The analytical solution was concentrated by vacuum decompression at 50 to 55°C by about 18 to 20 times, then cooled to room temperature, and then crystallized at a low temperature of 4 to 6°C, stirred for about 12 hours for crystallization, filtered, and vacuum dried at 50°C for 3 to 4 hours to obtain a crude product of nelarabine with a yield of 86%.
[0220] The crude nelarabine was recrystallized with anhydrous methanol at 60°C to obtain nelarabine crystalline powder, which was filtered and dried to obtain the finished nelarabine with an HPLC purity of more than 98% and a yield of 81%.
[0221] For the purpose of description and disclosure, all patents, patent applications and other identified publications are expressly incorporated herein by reference. These publications are provided only because they are disclosed prior to the filing date of the present application. All statements regarding the dates of these documents or the representations of the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the correctness of the dates of these documents or the contents of these documents. Furthermore, any reference to these publications herein does not constitute an admission that the publications are part of the common general knowledge in the art in any country.
[0222] Those skilled in the art will recognize that the scope of the present disclosure is not limited to the various specific implementations and examples described above, but that various modifications, substitutions, or re-combinations can be made without departing from the spirit and concept of the present disclosure, which all fall within the scope of protection of the present disclosure.
Claims
1. A recombinant genetically engineered bacterium 7N04 for preparing nelarabine, wherein: The recombinant genetically engineered bacterium 7N04 is an Escherichia coli containing genes for co-expressing uridine nucleoside phosphorylase and purine nucleoside phosphorylase, and its deposit number is CCTCC No. M2021490.
2. The recombinant genetically engineered bacterium 7N04 according to claim 1, wherein The recombinant genetically engineered bacteria is in the form of wet cells, which are obtained by inoculating the recombinant genetically engineered bacteria 7N04, fermenting and culturing, and collecting after the fermentation is terminated, wherein the ratio of uridine nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the wet cells is 1:1 to 1:3; Alternatively, the uridine nucleoside phosphorylase activity in the wet cells is 750-800 U / mL wet cells, and the purine nucleoside phosphorylase activity is 1750-1850 U / mL wet cells.
3. A microbial preparation comprising wet cells of the recombinant genetically engineered bacterium 7N04 according to claim 1 or 2.
4. A bio-enzyme catalyst containing a crude enzyme solution, wherein the bio-enzyme catalyst is obtained by using the recombinant genetically engineered bacterium 7N04 according to claim 1 or 2.
5. The bioenzyme catalyst according to claim 4, wherein The ratio of uridine nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the crude enzyme solution is 1:1 to 1:3; Alternatively, the uridine nucleoside phosphorylase activity in the crude enzyme solution is 800-900 U / mL crude enzyme solution, and the purine nucleoside phosphorylase activity is 1800-1900 U / mL crude enzyme solution.
6. The bioenzyme catalyst according to claim 4 or 5, wherein The ratio of uridine nucleoside phosphorylase activity to purine nucleoside phosphorylase activity in the biological enzyme catalyst is 1:1 to 1:3; Alternatively, the uridine nucleoside phosphorylase activity in the bio-enzyme catalyst is 100-6000 U / mL bio-enzyme catalyst, and the purine nucleoside phosphorylase activity is 200-12000 U / mL bio-enzyme catalyst.
7. A method for preparing the bio-enzyme catalyst according to any one of claims 4 to 6, comprising: (1) inoculating the recombinant genetically engineered bacteria 7N04 according to claim 1 or 2, fermenting and culturing, inducing protein expression with an inducer during the fermentation process, and collecting the bacteria after the fermentation is terminated; (2) Resuspending the bacterial cells in phosphate buffer, homogenizing under high pressure, and removing impurities at high temperature to obtain a bio-enzyme catalyst containing a crude enzyme solution.
8. The method of claim 7, wherein: The bio-enzyme catalyst also includes enzyme solution obtained by further concentrating and diluting the crude enzyme solution, or crude enzyme powder formed by further freeze-drying, or immobilized enzyme formed by further combining with an immobilized resin.
9. A method for preparing nelarabine, comprising: Using 2-amino-6-methoxypurine and uridine arabinoside as substrates, adding the bioenzyme catalyst according to any one of claims 4 to 6, carrying out a biotransformation reaction in a phosphate buffer, and separating and purifying to obtain nelarabine; Or, include: (1) inoculating the recombinant genetically engineered bacterium 7N04 with a deposit number of CCTCC No. M2021490 as described in claim 1 or 2, fermenting and culturing, inducing protein expression with an inducer during the fermentation process, and collecting the bacterial cells after the fermentation is terminated; (2) resuspending the bacterial cells in phosphate buffer, homogenizing under high pressure, and removing impurities at high temperature to obtain a bio-enzyme catalyst containing a crude enzyme solution; (3) Using 2-amino-6-methoxypurine and uridine arabinoside as substrates, adding a bio-enzyme catalyst to a phosphate buffer solution, carrying out a biotransformation reaction, and separating and purifying nelarabine.
10. The method of claim 9, wherein: The pressure of the high pressure homogenization is 600-1200 bar; Alternatively, the temperature of the high-temperature impurity removal is 50-70°C.
11. The method according to claim 9 or 10, wherein The phosphate buffer comprises a solution of dihydrogen phosphate and its conjugate base dihydrogen phosphate.
12. The method according to claim 9 or 10, wherein The phosphate buffer is a solution of dipotassium hydrogen phosphate and potassium dihydrogen phosphate.
13. The method according to claim 9 or 10, wherein The pH of the phosphate buffer is 6.5-8.0 or 6.8-8.
0.
14. The method according to claim 9 or 10, wherein In step (2), the weight ratio of the bacterial cells to the phosphate buffer is 1:5 to 1:
10.
15. The method of claim 9, wherein: The temperature of the bioconversion reaction is 50-85°C; Alternatively, the rotation speed of the bioconversion reaction is 60 to 500 rpm.
16. The method of claim 9, wherein: The concentration of 2-amino-6-methoxypurine is 5-35 g / L, and the concentration of arabinuridine is 10-70 g / L; Alternatively, the molar ratio of the substrate 2-amino-6-methoxypurine to uridine arabinoside is 1:1 to 1:
3.
17. Use of the recombinant genetically engineered bacterium 7N04 according to claim 1 or 2, the microbial preparation according to claim 3, or the bioenzyme catalyst according to any one of claims 4 to 6 for preparing nelarabine.
